You are in: eMedicine Specialties > Obstetrics and Gynecology > Infections OophoritisArticle Last Updated: Aug 14, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Arthur T Ollendorff, MD, Associate Professor of Clinical Obstetrics and Gynecology, Residency Program Director, Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine; Chief of Gynecology, Veterans Affairs Medical Center, Cincinnati Arthur T Ollendorff is a member of the following medical societies: American College of Obstetricians and Gynecologists and American Public Health Association Editors: Ronald Levine, MD, Director, Section of Gynecologic Endoscopy, Professor, Department of Obstetrics and Gynecology, University of Louisville School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Antonio V Sison, MD, FACOG, Program Director, Department of Obstetrics and Gynecology, Robert Wood Johnson University Hospital; Frederick B Gaupp, MD, Consulting Staff, Department of Family Practice, Assumption Community Hospital; Michel E Rivlin, MD, Associate Professor, Coordinator, Quality Assurance/Quality Improvement, Department of Obstetrics and Gynecology, University of Mississippi School of Medicine Author and Editor Disclosure Synonyms and related keywords: oophoritis, pelvic inflammatory disease, PID, tubo-ovarian abscess, TOA, ectopic pregnancy, infertility, chronic pelvic pain, Gonorrhea, Chlamydia, inflammation of the ovary, infection of the ovaries, sterilization INTRODUCTIONBackgroundOophoritis (ie, inflammation of the ovary) is an uncommonly used term for pelvic inflammatory disease (PID). This is an ascending infection of the ovaries and a major cause of female infectious morbidity, ectopic pregnancy, and sterilization. Oophoritis is a clinically diagnosed disease that must be carefully distinguished from other causes of abdominal pain. PathophysiologyInfection ascends from bacterial colonization of the cervix and extends to the uterus, fallopian tubes, and ovaries. Gonorrhea and Chlamydia species are typically colonized from the cervix in cases of oophoritis, but these pathogens are rarely isolated in ovarian tissue. These organisms instead facilitate infection of the adnexa by other bacteria. If left untreated, an abscess may form around the fallopian tubes and ovaries, a condition known as a tubo-ovarian abscess (TOA). FrequencyUnited StatesOne million cases are reported each year. InternationalWorldwide incidence and prevalence rates are unknown. Mortality/MorbidityIn the United States, the Centers for Disease Control and Prevention (CDC) estimate that 150 women die each year and 100,000 women become infertile due to oophoritis. The other major morbidities are an increased risk of ectopic pregnancy and chronic pelvic pain. AgeOophoritis most commonly occurs in women younger than 25 years. When oophoritis occurs in postmenopausal women, it is usually associated with an underlying gynecologic malignancy. CLINICALHistory
Physical
Causes
DIFFERENTIALSAdnexal Tumors Appendicitis Cystitis, Nonbacterial Diverticulitis Ectopic Pregnancy Gastroenteritis, Bacterial Gastroenteritis, Viral Mesenteric Lymphadenitis
|
| Drug Name | Ceftriaxone (Rocephin) |
|---|---|
| Description | Third-generation cephalosporin with broad-spectrum, gram-negative activity; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms. Arrests bacterial growth by binding to one or more penicillin-binding proteins. Considered first-line treatment (in conjunction with doxycycline) for outpatient management of PID. |
| Adult Dose | 250 mg IM once |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase ceftriaxone levels; coadministration with ethacrynic acid, furosemide, and aminoglycosides may increase nephrotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal impairment; caution in breastfeeding women and allergy to penicillin |
| Drug Name | Doxycycline (Vibramycin) |
|---|---|
| Description | Inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Used in conjunction with ceftriaxone or cefoxitin for outpatient treatment of PID. |
| Adult Dose | 100 mg PO bid for 14 d |
| Pediatric Dose | <8 years: Not recommended >8 years: Not established |
| Contraindications | Documented hypersensitivity, severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; tetracyclines can increase hypoprothrombinemic effects of anticoagulants; tetracyclines can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
| Drug Name | Cefoxitin (Mefoxin) |
|---|---|
| Description | Second-generation cephalosporin indicated for gram-positive cocci and gram-negative rod infections. Infections caused by cephalosporin- or penicillin-resistant gram-negative bacteria may respond to cefoxitin. For inpatient treatment of PID, cefoxitin and doxycycline in conjunction are considered first-line therapy. |
| Adult Dose | 2 g IV q6h until clinical improvement for 48-72 h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase effects of cefoxitin; coadministration with aminoglycosides or furosemide may increase nephrotoxicity (closely monitor renal function) |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged use or repeated treatment; caution in patients with previously diagnosed colitis |
| Drug Name | Gentamicin (Garamycin) |
|---|---|
| Description | Aminoglycoside antibiotic for gram-negative coverage. Used in combination with both an agent against gram-positive organisms and one that covers anaerobes. Gentamicin and clindamycin are second-line agents for inpatient treatment of oophoritis. |
| Adult Dose | Loading dose: 2 mg/kg IV, then 1.5 mg/kg IV q8h; continue until clinical improvement for 48-72 h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity, non–dialysis-dependent renal insufficiency |
| Interactions | Coadministration with other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; aminoglycosides enhance effects of neuromuscular blocking agents, thus prolonged respiratory depression may occur; coadministration with loop diuretics may increase auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (monitor regularly) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Narrow therapeutic index (not intended for long-term therapy); caution in renal failure (not on dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes causing RNA-dependent protein synthesis to arrest. Used in conjunction with gentamicin as second-line treatment for oophoritis. |
| Adult Dose | 900 mg IV q8h; continue until clinical improvement for 48-72 h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity, regional enteritis, ulcerative colitis, hepatic impairment, or antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade, induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay absorption of clindamycin |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis by allowing overgrowth of Clostridium difficile |
| Drug Name | Ampicillin (Marcillin, Omnipen) |
|---|---|
| Description | Used in conjunction with gentamicin and clindamycin for added enterococcus coverage. Usually added if gentamicin and clindamycin do not yield the desired clinical result. |
| Adult Dose | 2 g IV q6h |
| Pediatric Dose | None reported |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid and disulfiram elevate levels; allopurinol decreases effects and has additive effects on ampicillin rash; may decrease effects of oral contraceptives |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction |
Continue IV antibiotics until the patient is afebrile for 24 hours. If patients are placed on gentamicin and clindamycin and do not respond to this antibiotic coverage, add ampicillin to provide coverage for enterococci. Metronidazole (Flagyl) may be substituted for clindamycin if a tubo-ovarian abscess (TOA) is present.
Arrange for a follow-up visit within 48-72 hours of treatment (outpatient) or discharge from hospital to evaluate the treatment's success. Pain may take 7-10 days to abate.
Continue patients on doxycycline for a total of 14 days. Nonsteroidal anti-inflammatory drugs (NSAIDs) can be used for pain control.
Transfer is typically unnecessary.
Ninety percent of patients with PID respond to medical therapy if no TOA is present. Most patients respond to IV antibiotics alone if a TOA is smaller than 7 cm.
Article Last Updated: Aug 14, 2007